{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:53:47Z","timestamp":1794048827920,"version":"4.8.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27245-w","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:18:40Z","timestamp":1764857920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of macrolide therapy on clinical outcomes in hospitalized pneumonia patients: a retrospective study from Lebanese hospitals"],"prefix":"10.1038","volume":"15","author":[{"given":"Ramona","family":"Nasr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias A.","family":"Rahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadia","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir Abdel","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"27245_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13670-014-0112-7","volume":"4","author":"TR Breen","year":"2015","unstructured":"Breen, T. R. & File, T. M. Community-acquired pneumonia in older adults. Curr. Geriatr. Rep. 4, 51\u201359 (2015).","journal-title":"Curr. Geriatr. Rep."},{"key":"27245_CR2","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/cid\/ciy723","volume":"68","author":"MF Di Pasquale","year":"2019","unstructured":"Di Pasquale, M. F. et al. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin. Infect. Dis. 68, 1482\u20131493 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"27245_CR3","doi-asserted-by":"publisher","first-page":"e713","DOI":"10.1093\/infdis\/jiae639","volume":"231","author":"J Wei","year":"2025","unstructured":"Wei, J., Walker, A. S. & Eyre, D. W. Addition of macrolide antibiotics for hospital treatment of community-acquired pneumonia. J. Infect. Dis. 231, e713\u2013e722 (2025).","journal-title":"J. Infect. Dis."},{"key":"27245_CR4","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay, J. P. et al. Diagnosis And treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society And infectious diseases society of America. Am. J. Respir Crit. Care Med. 200, e45\u2013e67 (2019).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"27245_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.12788\/jhm.3444","volume":"15","author":"CD Jackson","year":"2020","unstructured":"Jackson, C. D., Burroughs-Ray, D. C. & Summers, N. A. Clinical guideline highlights for the hospitalist: 2019 American thoracic society\/infectious diseases society of America update on community-acquired pneumonia. J. Hosp. Med. 15, 743\u2013745 (2020).","journal-title":"J. Hosp. Med."},{"key":"27245_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004418.pub4","author":"N Eliakim-Raz","year":"2012","unstructured":"Eliakim-Raz, N. et al. Empiric antibiotic coverage of atypical pathogens for community\u2010acquired pneumonia in hospitalized adults. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD004418.pub4 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"27245_CR7","doi-asserted-by":"publisher","first-page":"102095","DOI":"10.1016\/j.pupt.2021.102095","volume":"71","author":"J Pollock","year":"2021","unstructured":"Pollock, J. & Chalmers, J. D. The Immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulm Pharmacol. Ther. 71, 102095 (2021).","journal-title":"Pulm Pharmacol. Ther."},{"key":"27245_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","volume":"68","author":"P Zarogoulidis","year":"2012","unstructured":"Zarogoulidis, P. et al. Macrolides: from in vitro anti-inflammatory and Immunomodulatory properties to clinical practice in respiratory diseases. Eur. J. Clin. Pharmacol. 68, 479\u2013503 (2012).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"27245_CR9","doi-asserted-by":"crossref","unstructured":"Zimmermann, P., Ziesenitz, V. C., Curtis, N. & Ritz, N. The Immunomodulatory effects of macrolides\u2014a systematic review of the underlying mechanisms. Front. Immunol. 9, 7456 (2018).","DOI":"10.3389\/fimmu.2018.00302"},{"key":"27245_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1183\/09031936.00042208","volume":"33","author":"PJ Crosbie","year":"2008","unstructured":"Crosbie, P. J. & Woodhead, M. A. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur. Respir J. 33, 171\u2013181 (2008).","journal-title":"Eur. Respir J."},{"key":"27245_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/jac\/dkh519","volume":"55","author":"GW Amsden","year":"2005","unstructured":"Amsden, G. W. Anti-inflammatory effects of macrolides\u2014an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother. 55, 10\u201321 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"27245_CR12","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1001\/jama.2014.4304","volume":"311","author":"EM Mortensen","year":"2014","unstructured":"Mortensen, E. M. et al. Association of Azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 311, 2199\u20132208 (2014).","journal-title":"JAMA"},{"key":"27245_CR13","doi-asserted-by":"publisher","first-page":"f1235","DOI":"10.1136\/bmj.f1235","volume":"346","author":"S Schembri","year":"2013","unstructured":"Schembri, S. et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 346, f1235 (2013).","journal-title":"BMJ"},{"key":"27245_CR14","doi-asserted-by":"crossref","unstructured":"Hansen, M. P. et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst. Rev. 1, 14526 (2019).","DOI":"10.1002\/14651858.CD011825.pub2"},{"key":"27245_CR15","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1086\/429242","volume":"40","author":"OG Vanderkooi","year":"2005","unstructured":"Vanderkooi, O. G., Low, D. E., Green, K., Powis, J. E. & McGeer, A. Predicting antimicrobial resistance in invasive Pneumococcal infections. Clin. Infect. Dis. 40, 1288\u20131297 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"27245_CR16","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S1473-3099(18)30444-4","volume":"19","author":"KS O\u2019Brien","year":"2019","unstructured":"O\u2019Brien, K. S. et al. Antimicrobial resistance following mass Azithromycin distribution for trachoma: a systematic review. Lancet Infect. Dis. 19, e14\u2013e25 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"27245_CR17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.chest.2018.11.006","volume":"155","author":"A Ceccato","year":"2019","unstructured":"Ceccato, A. et al. Effect of combined \u03b2-lactam\/macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with community-acquired pneumonia. CHEST 155, 795\u2013804 (2019).","journal-title":"CHEST"},{"key":"27245_CR18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1001\/jamapediatrics.2017.3225","volume":"171","author":"DJ Williams","year":"2017","unstructured":"Williams, D. J. et al. Effectiveness of \u03b2-Lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia. JAMA Pediatr. 171, 1184\u20131191 (2017).","journal-title":"JAMA Pediatr."},{"key":"27245_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1086\/367541","volume":"36","author":"JA Mart\u00ednez","year":"2003","unstructured":"Mart\u00ednez, J. A. et al. Addition of a macrolide to a \u03b2-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic Pneumococcal pneumonia. Clin. Infect. Dis. 36, 389\u2013395 (2003).","journal-title":"Clin. Infect. Dis."},{"key":"27245_CR20","doi-asserted-by":"publisher","first-page":"R265","DOI":"10.1186\/cc13095","volume":"17","author":"C Adrie","year":"2013","unstructured":"Adrie, C. et al. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance. Crit. Care. 17, R265 (2013).","journal-title":"Crit. Care"},{"key":"27245_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1183\/09031936.00031007","volume":"30","author":"M Paul","year":"2007","unstructured":"Paul, M. et al. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur. Respir J. 30, 525\u2013531 (2007).","journal-title":"Eur. Respir J."},{"key":"27245_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","volume":"42","author":"WI Sligl","year":"2014","unstructured":"Sligl, W. I. et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit. Care Med. 42, 420\u2013432 (2014).","journal-title":"Crit. Care Med."},{"key":"27245_CR23","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.2147\/COPD.S136245","volume":"12","author":"BH Mahboub","year":"2017","unstructured":"Mahboub, B. H. et al. Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and middle East-North Africa region, 2017. Int. J. Chron. Obstruct Pulmon Dis. 12, 2869\u20132890 (2017).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"27245_CR24","unstructured":"Cherry, D. & Greenpeace Lebanon\u2019s death rate and economic cost due to air pollution among the highest in the MENA region. Greenpeace (2020). https:\/\/www.greenpeace.org\/mena\/en\/appr\/"},{"key":"27245_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2147\/CLEP.S26350","volume":"3","author":"M Waked","year":"2011","unstructured":"Waked, M., Khayat, G. & Salameh, P. Chronic obstructive pulmonary disease prevalence in lebanon: a cross-sectional descriptive study. Clin. Epidemiol. 3, 315\u2013323 (2011).","journal-title":"Clin. Epidemiol."},{"key":"27245_CR26","unstructured":"ACAPS. Lebanon: The Effect of the Socioeconomic Crisis on Healthcare  8 (2023). https:\/\/www.acaps.org\/fileadmin\/Data_Product\/Main_media\/20231019_ACAPS_thematic_report_Lebanon_effect_of_socioeconomic_crisis_on_healthcare.pdf."},{"key":"27245_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4103\/atm.atm_49_23","volume":"18","author":"T Oreibi","year":"2023","unstructured":"Oreibi, T. et al. Outcomes of patients admitted to the intensive care unit with community-acquired pneumonia in a tertiary care center in Riyadh, Saudi Arabia. Ann. Thorac. Med. 18, 206\u2013210 (2023).","journal-title":"Ann. Thorac. Med."},{"key":"27245_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.12816\/0002626","volume":"62","author":"R Moghnieh","year":"2014","unstructured":"Moghnieh, R. et al. The Lebanese society for infectious diseases and clinical microbiology (LSIDCM) guidelines for adult Community-Acquired pneumonia (CAP) in Lebanon. Leban. Med. J. 62, 40\u201348 (2014).","journal-title":"Leban. Med. J."},{"key":"27245_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/resp.13233","volume":"23","author":"MI Restrepo","year":"2018","unstructured":"Restrepo, M. I. & Reyes, L. F. Pneumonia as a cardiovascular disease. Respirology 23, 250\u2013259 (2018).","journal-title":"Respirology"},{"key":"27245_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/s12913-017-2528-1","volume":"17","author":"F El-Jardali","year":"2017","unstructured":"El-Jardali, F. & Fadlallah, R. A review of National policies and strategies to improve quality of health care and patient safety: a case study from Lebanon and Jordan. BMC Health Serv. Res. 17, 568 (2017).","journal-title":"BMC Health Serv. Res."},{"key":"27245_CR31","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1445-5994.2012.02880.x","volume":"42","author":"T Bayles","year":"2012","unstructured":"Bayles, T., Tong, E., Choo, S. & Cheng, A. C. Clarithromycin for community-acquired pneumonia: beware drug interactions. Intern. Med. J. 42, 1165\u20131166 (2012).","journal-title":"Intern. Med. J."},{"key":"27245_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.idc.2009.06.013","volume":"23","author":"JM Zuckerman","year":"2009","unstructured":"Zuckerman, J. M., Qamar, F. & Bono, B. R. Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, Tigecycline. Infect. Dis. Clin. North. Am. 23, 997\u20131026 (2009).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"27245_CR33","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell, L. A. et al. Infectious diseases society of America\/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44, S27\u2013S72 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"27245_CR34","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-6121400\/v1","author":"M Wang","year":"2025","unstructured":"Wang, M. et al. Comparison of the efficacy of initial empirical antibiotic regimens in severe community-acquired pneumonia: a network meta-analysis. Preprint at. https:\/\/doi.org\/10.21203\/rs.3.rs-6121400\/v1 (2025).","journal-title":"Preprint at."},{"key":"27245_CR35","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jac\/dku033","volume":"69","author":"W Nie","year":"2014","unstructured":"Nie, W., Li, B. & Xiu, Q. \u03b2-Lactam\/macrolide dual therapy versus \u03b2-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J. Antimicrob. Chemother. 69, 1441\u20131446 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"27245_CR36","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/resp.12835","volume":"21","author":"N Horita","year":"2016","unstructured":"Horita, N. et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis. Respirology 21, 1193\u20131200 (2016).","journal-title":"Respirology"},{"key":"27245_CR37","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","volume":"174","author":"N Garin","year":"2014","unstructured":"Garin, N. et al. \u03b2-lactam monotherapy vs \u03b2-lactam\u2013macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern. Med. 174, 1894\u20131901 (2014).","journal-title":"JAMA Intern. Med."},{"key":"27245_CR38","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","volume":"372","author":"DF Postma","year":"2015","unstructured":"Postma, D. F. et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl. J. Med. 372, 1312\u20131323 (2015).","journal-title":"N Engl. J. Med."},{"key":"27245_CR39","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1164\/rccm.201502-0212OC","volume":"191","author":"C Cilloniz","year":"2015","unstructured":"Cilloniz, C. et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am. J. Respir Crit. Care Med. 191, 1265\u20131272 (2015).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"27245_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3346\/jkms.2017.32.1.77","volume":"32","author":"JH Lee","year":"2017","unstructured":"Lee, J. H., Kim, H. J. & Kim, Y. H. Is \u03b2-lactam plus macrolide more effective than \u03b2-lactam plus fluoroquinolone among patients with severe community-acquired pneumonia? A systemic review and meta-analysis. J. Korean Med. Sci. 32, 77\u201384 (2017).","journal-title":"J. Korean Med. Sci."},{"key":"27245_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.idc.2009.04.003","volume":"23","author":"MI Restrepo","year":"2009","unstructured":"Restrepo, M. I. & Anzueto, A. Severe community-acquired pneumonia. Infect. Dis. Clin. North. Am. 23, 503\u2013520 (2009).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"27245_CR42","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3390\/ijms17122120","volume":"17","author":"C Cilloniz","year":"2016","unstructured":"Cilloniz, C., Martin-Loeches, I., Garcia-Vidal, C., San Jose, A. & Torres, A. Microbial etiology of pneumonia: epidemiology, diagnosis and resistance patterns. Int. J. Mol. Sci. 17, 2120 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"27245_CR43","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jama.2016.2691","volume":"315","author":"LA van Vught","year":"2016","unstructured":"van Vught, L. A. et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315, 1469\u20131479 (2016).","journal-title":"JAMA"},{"key":"27245_CR44","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/CMR.00078-09","volume":"23","author":"S Kanoh","year":"2010","unstructured":"Kanoh, S. & Rubin, B. K. Mechanisms of action and clinical application of macrolides as Immunomodulatory medications. Clin. Microbiol. Rev. 23, 590\u2013615 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"27245_CR45","doi-asserted-by":"publisher","first-page":"11038","DOI":"10.3390\/ijms241311038","volume":"24","author":"R Anderson","year":"2023","unstructured":"Anderson, R. & Feldman, C. The global burden of community-acquired pneumonia in adults, encompassing invasive Pneumococcal disease and the prevalence of its associated cardiovascular events, with a focus on Pneumolysin and macrolide antibiotics in pathogenesis and therapy. Int. J. Mol. Sci. 24, 11038 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"27245_CR46","doi-asserted-by":"publisher","first-page":"030006052110499","DOI":"10.1177\/03000605211049943","volume":"49","author":"J Al-Salloum","year":"2021","unstructured":"Al-Salloum, J., Gillani, S. W., Mahmood, R. K. & Gulam, S. M. Comparative efficacy of Azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review. J. Int. Med. Res. 49, 03000605211049943 (2021).","journal-title":"J. Int. Med. Res."},{"key":"27245_CR47","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/antibiotics11091193","volume":"11","author":"B Viaggi","year":"2022","unstructured":"Viaggi, B. et al. Tissue penetration of antimicrobials in intensive care unit patients: a systematic review\u2014part II. Antibiotics 11, 1193 (2022).","journal-title":"Antibiotics"},{"key":"27245_CR48","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41479-017-0025-2","volume":"9","author":"N Rae","year":"2017","unstructured":"Rae, N., Singanayagam, A., Schembri, S. & Chalmers, J. D. Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study. Pneumonia 9, 2 (2017).","journal-title":"Pneumonia"},{"key":"27245_CR49","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1128\/AAC.44.7.1796-1802.2000","volume":"44","author":"J Plouffe","year":"2000","unstructured":"Plouffe, J. et al. Clinical efficacy of intravenous followed by oral Azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 44, 1796\u20131802 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"27245_CR50","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1001\/jama.2020.4437","volume":"323","author":"PK Lindenauer","year":"2020","unstructured":"Lindenauer, P. K. et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries. JAMA 323, 1813\u20131823 (2020).","journal-title":"JAMA"},{"key":"27245_CR51","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1164\/rccm.200708-1238OC","volume":"177","author":"V Nobre","year":"2008","unstructured":"Nobre, V., Harbarth, S., Graf, J. D., Rohner, P. & Pugin, J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients. Am. J. Respir Crit. Care Med. 177, 498\u2013505 (2008).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"27245_CR52","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1365-2362.2010.02259.x","volume":"40","author":"P Schuetz","year":"2010","unstructured":"Schuetz, P. et al. Serum procalcitonin, C-reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study. Eur. J. Clin. Invest. 40, 376\u2013381 (2010).","journal-title":"Eur. J. Clin. Invest."},{"key":"27245_CR53","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/cid\/cir408","volume":"53","author":"R Agarwal","year":"2011","unstructured":"Agarwal, R. & Schwartz, D. N. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin. Infect. Dis. 53, 379\u2013387 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"27245_CR54","doi-asserted-by":"publisher","first-page":"339","DOI":"10.32457\/ijmss.2014.042","volume":"1","author":"M Cant\u00edn","year":"2014","unstructured":"Cant\u00edn, M. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. Reviewing the latest version. Int. J. Med. Surg. Sci. 1, 339\u2013346 (2014).","journal-title":"Int. J. Med. Surg. Sci."},{"key":"27245_CR55","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13054-023-04466-x","volume":"27","author":"LF Reyes","year":"2023","unstructured":"Reyes, L. F. et al. Impact of macrolide treatment on long-term mortality in patients admitted to the ICU due to CAP: a targeted maximum likelihood Estimation and survival analysis. Crit. Care. 27, 212 (2023).","journal-title":"Crit. Care"},{"key":"27245_CR56","doi-asserted-by":"publisher","unstructured":"Choi, H. et al. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium Massiliense lung disease. Antimicrob. Agents Chemother. 61, 2563.  https:\/\/doi.org\/10.1128\/aac.02189-16 (2017).","DOI":"10.1128\/aac.02189-16"},{"key":"27245_CR57","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.3390\/jcm12206526","volume":"12","author":"FJ Candel","year":"2023","unstructured":"Candel, F. J. et al. Ten issues to update in nosocomial or hospital-acquired pneumonia: an expert review. J. Clin. Med. 12, 6526 (2023).","journal-title":"J. Clin. Med."},{"key":"27245_CR58","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00134-023-07295-2","volume":"50","author":"L Kreitmann","year":"2024","unstructured":"Kreitmann, L. et al. ICU-acquired infections in immunocompromised patients. Intensive Care Med. 50, 332\u2013349 (2024).","journal-title":"Intensive Care Med."},{"key":"27245_CR59","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.rmed.2018.05.020","volume":"140","author":"FW Arnold","year":"2018","unstructured":"Arnold, F. W. et al. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respir Med. 140, 115\u2013121 (2018).","journal-title":"Respir Med."},{"key":"27245_CR60","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4187\/respcare.06314","volume":"63","author":"DM Williams","year":"2018","unstructured":"Williams, D. M. Clinical Pharmacology of corticosteroids. Respir Care. 63, 655\u2013670 (2018).","journal-title":"Respir Care"},{"key":"27245_CR61","doi-asserted-by":"publisher","first-page":"e0238215","DOI":"10.1371\/journal.pone.0238215","volume":"15","author":"P Ssentongo","year":"2020","unstructured":"Ssentongo, P., Ssentongo, A. E., Heilbrunn, E. S., Ba, D. M. & Chinchilli, V. M. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLOS ONE. 15, e0238215 (2020).","journal-title":"PLOS ONE"},{"key":"27245_CR62","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan, H. et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care. 43, 1130\u20131139 (2005).","journal-title":"Med. Care"},{"key":"27245_CR63","doi-asserted-by":"publisher","first-page":"648","DOI":"10.21105\/joss.00648","volume":"3","author":"A Gasparini","year":"2018","unstructured":"Gasparini, A. Comorbidity: an R package for computing comorbidity scores. J. Open. Source Softw. 3, 648 (2018).","journal-title":"J. Open. Source Softw."},{"key":"27245_CR64","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/resp.13663","volume":"25","author":"D Villafuerte","year":"2020","unstructured":"Villafuerte, D. et al. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia. Respirology 25, 543\u2013551 (2020).","journal-title":"Respirology"},{"key":"27245_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/iwj.12545","volume":"14","author":"SA Van Asten","year":"2017","unstructured":"Van Asten, S. A. et al. The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis. Int. Wound J. 14, 40\u201345 (2017).","journal-title":"Int. Wound J."},{"key":"27245_CR66","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1001\/archinte.159.21.2576","volume":"159","author":"JE Stahl","year":"1999","unstructured":"Stahl, J. E., Barza, M., DesJardin, J., Martin, R. & Eckman, M. H. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. 159, 2576\u20132580 (1999).","journal-title":"Arch. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27245-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27245-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27245-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:02:22Z","timestamp":1764864142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27245-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27245"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27245-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the ethical committees of participating hospitals: Mount Lebanon University Medical Center (Approval ID: MLH\u2013D-2025-002); and Ain Wazein Medical Village (Approval ID: CRU 404). This study ensures complete anonymity of the collected data, as no personally identifiable information was recorded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"43155"}}